Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...
Hosted on MSN10mon
Arrowhead CEO says Helldivers 2 balancing patches have 'gone too far' recently: 'It feels like every time someone finds something fun, the fun is removed'Arrowhead has rolled out a handful of sweeping ... "It feels like every time someone finds something fun, the fun is removed." In a followup tweet, Pilestedt says he's seeing "a bit too much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback